Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting
Taysha Gene Therapies (Nasdaq: TSHA), a biotechnology firm advancing AAV-based gene therapies for severe CNS diseases, will present clinical data from its REVEAL Phase 1/2 trials assessing TSHA-102 for Rett syndrome. The company will host a webcast on June 18, 2024, at 8:00 AM Eastern Time, and the data will also be shared at the 2024 IRSF Rett Syndrome Scientific Meeting on June 18-19, 2024. Presentations will feature data from both adolescent/adult and pediatric trials, delivered by Dr. Elsa Rossignol and Dr. Colleen Buhrfiend. The webcast can be accessed via Taysha’s website.
- Taysha to present new clinical data from the REVEAL Phase 1/2 trials, indicating progress in TSHA-102 development.
- Webcast and scientific meeting presentation increases visibility and credibility within the scientific community.
- Presence at 2024 IRSF Rett Syndrome Scientific Meeting highlights Taysha's commitment to Rett syndrome research.
- Multiple presentations by reputable physicians Dr. Elsa Rossignol and Dr. Colleen Buhrfiend add authority and reliability to the data shared.
- No specific clinical data or trial results provided, leaving the effectiveness of TSHA-102 undefined.
- Increased expectations from the investors without concrete data could lead to volatility in stock price.
- Potential risks associated with the trials, including adverse effects, are not addressed.
- No details on the financial implications or funding status for ongoing research and trials.
Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time
Oral presentation by Elsa Rossignol, M.D., FRCP, FAAP, Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrfiend, M.D., of RUSH University Medical Center at the 2024 IRSF Rett Syndrome Scientific Meeting on Wednesday, June 19, 2024, at 11:00 AM Mountain Time
DALLAS, June 12, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will host a webcast on Tuesday, June 18, 2024, to discuss new clinical data from the REVEAL Phase 1/2 adolescent and adult trial and the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in Rett syndrome, as well as provide a program update. The data will also be presented at the 2024 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting taking place in Westminster, Colo., June 18-19, 2024.
| Taysha-Hosted Webcast Details |
| Date/Time: Tuesday, June 18, 2024, at 8:00 AM Eastern Time |
| Registration: https://lifescievents.com/event/taysha-2/ The live webcast and replay will be available through Taysha’s website here. |
| 2024 IRSF Rett Syndrome Scientific Meeting Presentation Details Poster Presentation Title: TSHA-102 gene therapy for Rett syndrome: First-cohort data from the REVEAL Adolescent/Adult and Pediatric studies Date/Time: Tuesday, June 18, 2024, 5:15-7:00 PM Mountain Time Presenters: Elsa Rossignol, M.D., FRCP, FAAP, Associate Professor in Neuroscience and Pediatrics at the Université de Montréal and Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrfiend, M.D., Assistant Professor of Pediatrics at RUSH University Medical Center |
| Oral Presentation Title: TSHA-102 gene therapy for Rett syndrome: First-cohort data from the REVEAL Adolescent/Adult and Pediatric studies Date/Time: Wednesday, June 19, 2024, at 11:00 AM Mountain Time Presenters: Elsa Rossignol, M.D., FRCP, FAAP, Associate Professor in Neuroscience and Pediatrics at the Université de Montréal and Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrfiend, M.D., Assistant Professor of Pediatrics at RUSH University Medical Center |
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
When will Taysha Gene Therapies present new clinical data for TSHA-102?
What type of gene therapy is Taysha Gene Therapies developing for Rett syndrome?
What will be discussed in Taysha's webcast on June 18, 2024?
Who are the presenters for the clinical data at the 2024 IRSF Rett Syndrome Scientific Meeting?
How can I access the live webcast hosted by Taysha Gene Therapies?
